Severe prolonged neutropenia following administration of tocilizumab in a patient affected by COVID-19: a case report and brief review of the literature

Tocilizumab is one of the newest therapeutic options for the acute respiratory distress syndrome (ARDS) caused by the recently discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) β-coronavirus. Several trials are currently ongoing to assess the efficacy and safety profile of toci...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernardo, Luca, Del Sesto, Stefania, Giordano, Laura, Benincaso, Anna Rita, Biondi, Piero, Goj, Vinicio, Ferrara, Francesca, Talenti, Antonella, Grisolia, Antonella, Ascierto, Paolo Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Therapy in Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487439/
https://www.ncbi.nlm.nih.gov/pubmed/32952393
http://dx.doi.org/10.1007/s40267-020-00777-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487439/
https://www.ncbi.nlm.nih.gov/pubmed/32952393
http://dx.doi.org/10.1007/s40267-020-00777-z

Ejemplares similares